TSS
ELDN icon

Two Sigma Securities’s Eledon Pharmaceuticals ELDN Stock Holding History

Two Sigma Securities’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,345
Closed -$29.2K – 1781
2025
Q4 		$29.2K Buy
+19,345
New +$46K ﹤0.01% 1130
2024
Q4 		– Sell
-11,027
Closed -$27.5K – 2101
2024
Q3 		$27.5K Buy
+11,027
New +$29.5K ﹤0.01% 2443
2024
Q1 		– Sell
-11,780
Closed -$21.2K – 3115
2023
Q4 		$21.2K Buy
+11,780
New +$16.4K ﹤0.01% 2714
2020
Q3 		– Sell
-1,869
Closed -$15K – 1379
2020
Q2 		$15K Buy
+1,869
New +$21.1K ﹤0.01% 1297
2019
Q3 		– Sell
-1,258
Closed -$23K – 2139
2019
Q2 		$23K Buy
+1,258
New +$55K ﹤0.01% 1933
2018
Q4 		– Sell
-597
Closed -$50K – 2314
2018
Q3 		$50K Buy
+597
New +$60.9K ﹤0.01% 2360
2016
Q4 		– Sell
-74
Closed -$18K – 758
2016
Q3 		$18K Buy
+74
New +$27.1K 0.01% 606

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Two Sigma Securities's ELDN Position: Q1 2026 in Review

Two Sigma Securities sold out of Eledon Pharmaceuticals (ELDN) in Q1 2026, closing a stake of 19,345 shares — an estimated $29.2K sold.

Two Sigma Securities first reported a position in ELDN in Q3 2016 and held it in 7 quarters. The position peaked at $50K in Q3 2018. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Two Sigma Securities reported no remaining Eledon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 19,345 Eledon Pharmaceuticals shares in Q1 2026, an estimated $29.2K.
  • Two Sigma Securities first reported a position in Eledon Pharmaceuticals in Q3 2016 and held it in 7 quarters.
  • Two Sigma Securities's Eledon Pharmaceuticals position peaked at $50K in Q3 2018.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.